Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quantitative Neuromuscular Function Monitoring | Device | Quantitative electromyographic (EMG) monitoring |
| Measure | Description | Time Frame |
|---|---|---|
| Oxygen desaturation | Incidence and magnitude of significant oxygen desaturation | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| The rate of compliance with muscle relaxant monitoring and reversal protocols | Rate of compliance (%) | 24 hours |
| Total intraoperative rocuronium use | Total dose/kg/hr (mg/kg/hr) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients scheduled for surgical procedures in the UC Davis Medical Center main ORs will be screened for potential enrollment.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ana P Arias, BS | Contact | 916-703-5456 | apaarias@ucdavis.edu | |
| Julio J Arana Pineda, BA | Contact | 916-734-4074 | jjaranapineda@ucdavis.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UC Davis Medical Center | Recruiting | Sacramento | California | 95817 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Aug 28, 2025 | |
| Reset | Sep 17, 2025 | |
| Release | Jun 3, 2026 | |
| Reset | Jun 26, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Aug 28, 2025 | Sep 17, 2025 | |||
| Jun 3, 2026 |
Not provided
Not provided
Not provided
| 24 hours |
| Total sugammadex dose | Total dose (mg/kg) | 24 hours |
| Post-operative supplemental oxygen requirement | Oxygen requirement (FiO2%/hr) | 24 hours |
| Post-operative unit length of stay | Length of stay (Hours) | 7 days |
| Hospital Length of stay | Length of stay (Hours) | 7 days |
| Success rate for wearable device | Rate of compliance (%) | 24 hours |
| Jun 26, 2026 |